News at a glance

Ad hoc announcement

Galenica remains on growth track

Galenica Group sales grew 4.7% to CHF 2,999.7 million in the third quarter of 2025.Sales growth is driven by prescription drugs and dietary supplements.

 
Ad hoc announcement

Galenica demonstrates pleasing growth and improves EBIT guidance

Galenica Group sales grew by 5.0% to CHF 1,995.4 million in the first half of 2025.Adjusted EBIT1 increased by 10.9% to CHF 109.

 
Ad hoc announcement

Galenica to enter the diagnostics business by acquiring Labor Team

By acquiring the Labor Team Group, Galenica is adding a leading Swiss diagnostic service provider to its healthcare network.

 
Ad hoc announcement

Galenica continues sales growth

Sales growth of 4.7% to CHF 1,314.

 
Ad hoc announcement

Galenica continues to grow in 2024

With sales up 4.7% in the 2024 financial year, the Galenica Group grew strongly and generated consolidated net sales of CHF 3,921.1 million.

 
Ad hoc announcement

Galenica reports strong sales growth once again

Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million.

 
Ad hoc announcement

Galenica increases sales growth in the third quarter

Following solid sales growth of 2.6% in the first half of 2024, Galenica grew more strongly again in the third quarter and generated net sales of CHF 2,864.

 
Ad hoc announcement

Galenica achieves solid growth in a challenging market environment

Galenica Group sales grew by 2.6% to CHF 1,900.0 million in the first half of 2024.

 
Ad hoc announcement

Galenica on track with sales growth

The Galenica Group made a good start to the new year with sales growth of 4.8% to CHF 1,255.5 million in the first four months of 2024.

 
Ad hoc announcement

Galenica continues to grow in the 2023 financial year

The Galenica Group achieved strong growth with an increase in sales of 4.4% in the 2023 financial year and generated consolidated net sales of CHF 3,746.

 
Ad hoc announcement

Galenica again achieves strong sales growth

Galenica Group sales performed well in 2023, growing by 4.4% to CHF 3,746.0 million. As expected, sales growth of 3.

 
Ad hoc announcement

Galenica Investor Day: Updated mid-term guidance and strategy update

 
Ad hoc announcement

Galenica achieves strong sales growth in the first half of 2023

 
Ad hoc announcement

Galenica lowers EBIT guidance 2023 due to special factors – Sales and dividend outlook confirmed

 
Ad hoc announcement

Green light for Switzerland’s leading online pharmacy

 
Ad hoc announcement

Galenica and Shop Apotheke Europe enter into a strategic partnership and establish the leading online pharmacy in Switzerland

 
Ad hoc announcement

Galenica achieves strong results in 2022 and increases dividend again

 
Ad hoc announcement

Change to the Board of Directors of the Galenica Group

 
Ad hoc announcement

2022 Galenica Group sales

 
Ad hoc announcement

Galenica Group half-year results 2022

 
Ad hoc announcement

Annual results of the Galenica Group 2021

 
Ad hoc announcement

Strong increase in sales in 2021 and improved earnings outlook

 
Ad hoc announcement

Property sale has a positive impact on EBIT in 2021

 
Ad hoc announcement

Galenica Group half year results 2021

 
Ad hoc announcement

Positive sales growth and product acquisitions: Galenica raises sales and EBIT guidance 2021

 

Shaping tomorrow's healthcare system together.

Media inquiries & contact

Are you a journalist or editor and have questions about Galenica? Get in touch with us.

Media centre

Images, videos, logos: All downloads for reuse in media reports.

Information for investors

Invest in the strongest network in the Swiss healthcare market.

Here you will find information about our share price, as well as presentations, conferences and our financial calendar.

Woman holds Tablet
Woman holds Tablet